Skip to content

US raises tariffs on generic drugs from India

By News Analysis India · · 1 min read

A phased tariff regime on imported generics was unveiled by President Trump, aiming to curb dependence on overseas sources. Under the plan, imports from India will enjoy a tariff‑free period for the first two years. Starting in the third year, a 100 percent duty will be imposed, climbing to 200 percent in the fourth year. The White House argues the stepwise approach will encourage pharmaceutical firms to shift production back to American soil.

India, often called the “pharmacy of the world,” presently ships around $9.7 billion worth of medicines to the United States, representing roughly 38 percent of its total pharma exports. Generic drugs from Indian makers are used widely for diabetes, hypertension, mental‑health conditions, cancer and infectious diseases, and they dominate the birth‑control pill market, with two Indian companies supplying about 65 percent of prescriptions in 2024. The new tariffs could dramatically raise the cost of these medicines in the U.S. market if Indian companies continue to export without expanding U.S. manufacturing.

While the first two years provide a buffer, the long‑term outlook remains unclear. A February trade understanding between Washington and New Delhi had called for negotiations on generic pharmaceuticals and active ingredients, but the announced duty structure could override those talks unless a new agreement is reached.